Brief/Technical Note

Light Obscuration Measurements of Highly Viscous Solutions: Sample Pressurization Overcomes Underestimation of Subvisible Particle Counts

Daniel Weinbuch,^{1,2} Wim Jiskoot,² and Andrea Hawe^{1,3}

Received 30 January 2014; accepted 27 May 2014; published online 17 June 2014

ABSTRACT. Light obscuration (LO) is the current standard technique for subvisible particle analysis in the quality control of parenterally administered drugs, including therapeutic proteins. Some of those, however, exhibit high viscosities due to high protein concentrations, which can lead to false results by LO measurements. In this study, we show that elevated sample viscosities, from about 9 cP, lead to an underestimation of subvisible particle concentrations, which is easily overlooked when considering reported data alone. We evaluated a solution to this problem, which is the application of sample pressurization during analysis. The results show that this is an elegant way to restore the reliability of LO analysis of highly viscous products without the necessity of additional sample preparation.

KEY WORDS: high viscosity; light obscuration; protein formulation; subvisible particles.

INTRODUCTION

Regulatory authorities require all parentally administered drugs/products to be tested for subvisible particulate matter. Light obscuration (LO) is the primary method described by the current pharmacopeias (USP <788> and Ph.Eur. 2.9.19) for the quantification of subvisible particles in parenteral products (1,2). However, for biopharmaceutical products, other methods, such as flow imaging microscopy or electric zone sensing, are expected by the authorities as well (3). In light obscuration, a syringe pump draws the sample through the system where particulate contaminants or impurities block a certain amount of light from a laser beam. The resulting “shadow” is detected by an optical sensor and converted into an equivalent circular diameter. However, for highly viscous products, such as high-concentration protein formulations for subcutaneous administration (4), LO measurements are potentially compromised (5,6) and a more time-consuming microscopy method has to be used, which is not always applicable to amorphous protein particles (1). High protein concentrations can impede light obscuration measurements because of an increased refractive index of the solution. Herewith, the RI difference between proteinaceous particles and solution becomes so small that the particles become “invisible,” which has been investigated previously by our group (7). In this study we focused on the influence of high viscosity to show that elevated sample viscosities from about 9 cP lead to an underestimation of subvisible particle concentrations, which is easy to overlook

when considering reported data alone. We evaluated a solution to this problem involving the application of sample pressurization during analysis. The results show that this is an elegant way to restore the reliability of LO analysis of highly viscous products, *e.g.*, highly concentrated protein formulations, without necessitating additional sample preparation.

MATERIALS AND METHODS

Materials

Glycerol ($\geq 99\%$) was purchased from Sigma Aldrich (Steinheim, Germany) and pharmaceutical grade sucrose was provided by Südzucker (Mannheim, Germany). Polyclonal IgG (Hizentra®) was obtained from a local pharmacy. NIST traceable 2- μm polystyrene sizing standards were purchased from Thermo Scientific (Ulm, Germany).

Sample Preparation

Glycerol and sucrose solutions were prepared in purified water in the stated concentrations. A highly concentrated protein solution at elevated viscosity (48 cP) was obtained by upconcentration of polyclonal IgG (Hizentra®) from 200 to about 250 mg/mL by using a centrifugal filter unit with a 10-kDa molecular weight cutoff (Millipore, Schwalbach, Germany). Subsequently, all solutions were filtered through a 0.22- μm syringe filter (Millipore, Schwalbach, Germany). Samples were measured with or without the addition of polystyrene sizing standards (2 μm) in a final dilution of 1:10,000.

Light Obscuration

Particle concentrations in a size range between 1 and 200 μm were measured with a PAMAS SBSS

¹ Coriolis Pharma, Am Klopferspitz 19, 82152, Martinsried, Germany.

² Division of Drug Delivery Technology, Leiden Academic Centre for Drug Research, Leiden University, 2300 RA, Leiden, The Netherlands.

³ To whom correspondence should be addressed. (e-mail: Andrea.Hawe@coriolis-pharma.com)

Fig. 1. Schematic overview of the PAMAS SBSS light obscuration device

(Partikelmess- und Analysesysteme GmbH, Rutesheim, Germany) equipped with an HCB-LD-25/25 sensor, a 1-mL syringe pump, and a pressurizable sample chamber (Fig. 1). Four measurements of 0.3 mL with a pre-run volume of 0.2 mL and a fixed flow rate of 10 mL/min were performed following the current draft USP <787> method (5,6) with or without pressurization of the sample chamber at 4 bar above atmosphere. The mean particle concentration was calculated from the last three (out of four) measurements. Unless stated differently, samples were measured in triplicate and mean and standard deviations were calculated.

Viscosity Measurements

A Paar Physica MCR-100 rheometer (Anton Paar GmbH, Ostfildern-Scharnhausen, Germany) equipped with an MK22 cone was used to measure the dynamic viscosity of a 1-mL sample at 20°C every 5 s during a shear rate ramp from 50 to 500 s⁻¹ over 17 min with a cone-to-plate gap of 50 µm. All solutions showed Newtonian behavior. Samples

Fig. 3. Image of the PAMAS SBSS light obscuration syringe pump aspirating **a** purified water and **b** 75% (w/v) sucrose solution during sample measurement at ambient pressure conditions

were measured in triplicate and mean and standard deviations were calculated.

RESULTS AND DISCUSSION

Filtered solutions of sucrose and glycerol (0, 25, 50, and 75% w/v and v/v, respectively) were used to simulate high-viscosity samples. Analysis by light obscuration at 0 and 4 bar sample pressurization resulted in low background counts (<100 particles/mL >1 µm), showing that sample preparation and/or the light obscuration system itself introduce negligible quantities of foreign particulate matter (data not shown). Next, purified water, sucrose, and glycerol solutions were spiked with 2-µm polystyrene sizing standards, resulting in approximately 8×10^4 particles per milliliter, as measured in purified water at ambient pressure conditions (Fig. 2a). Results of the polystyrene sizing standards in purified water, measured under sample pressurization, showed similar particle counts. At increased concentrations of glycerol (>50% v/v) or sucrose (>75% w/v), however, particle concentrations apparently decreased when measured at ambient pressure conditions. A similar observation was made when a highly concentrated protein solution (polyclonal IgG at approximately 250 mg/mL) with a viscosity of about 48 cP spiked with 2-µm polystyrene sizing standards was measured. Here the determined particle concentration, derived from a single LO measurement, decreased from 8.2×10^4 particles per milliliter when measured at 4 bar to 4.3×10^4 particles per milliliter when measured without sample pressurization (Fig. 2b), showing the relevance of the problem to highly concentrated protein formulations.

Fig. 2. Measured particle concentrations by light obscuration, with and without sample pressurization, of **a** water and different glycerol and sucrose solutions and **b** high concentrated protein solution, all containing a fixed concentration of 2-µm polystyrene sizing standards. Error bars and values in brackets show standard deviations from triplicate particle concentration and viscosity measurements, respectively. * $p < 0.05$, ** $p < 0.005$ (based on one-way ANOVA)

The reduction in particle counts can be explained by an intake of air into the syringe pump of the LO system (Fig. 3). This air intake was also observed for the same highly concentrated glycerol and sucrose solutions without the addition of sizing standards, however, with no significant effect on the measured particle concentration. This indicates that the air bubbles did not pass the detector because their high refractive index makes them easily detectable by the system (7). Thus, the air enters the light obscuration system between sensor and syringe pump cell through tubing connections and/or valves, as a result of an under-pressure created by the slow-moving high-viscosity solutions. This results in a reduced measurement volume and, consequently, an underestimation of particle concentrations. The sample viscosity at which the effect started to occur in our tested system was approximately 9 cP (Fig. 2a), a value that can easily be reached in concentrated protein formulations (8).

Since the air intake may depend on the state of the system tubing and valves, two other light obscuration systems (type PAMAS SVSS)—one equipped with a 1-mL syringe pump and the other with a 10-mL one—were tested as well. All of the tested systems showed a similar air intake at very comparable viscosity values (results not shown). This indicates that it is a general problem that is not related to one specific PAMAS system. Moreover, depending on their maintenance state, individual LO systems might leak air at even lower viscosity values.

It is important to realize that the underestimation of particle concentration resulting from air intake may be overlooked when considering reported data alone. The syringe pump needs to be observed by the operator during method development and specifically tested for air intake when samples of increased viscosities are to be analyzed by LO. Alternatively, or in addition, one could follow the method described in this study and verify if counting or sizing standards spiked into water and into the formulation result in a similar increase in particle counts.

The application of light obscuration can, given the requirements of regulatory authorities and current pharmacopeias, only be circumvented by the application of microscopic techniques, which are more labor-intensive and less precise (9). The current draft USP <787>, which is tailored for the analysis of biopharmaceuticals, states that sample dilution with a low viscosity solvent (*e.g.*, purified water) is a possible “last resort” solution. This, however, may have an influence on the composition, distribution, or concentration of proteinaceous particles. Another more elegant way to measure high-viscosity solutions without sample dilution is the application of overpressure on the sample side. As shown in Fig. 2, the application of 4 bar above atmospheric pressure can restore the reliability of light obscuration measurements for highly viscous solutions with viscosities of up to at least 50 cP.

CONCLUSION

We have demonstrated that particle concentrations in highly viscous samples, as measured by light obscuration, are potentially underestimated. This is due to an intake of air into the measurement system and consequently a reduced measurement volume. Importantly, this can easily be overlooked

by the operator, since blank measurements are not affected, though they should be anticipated prior to the analysis of viscous samples. Sample pressurization is a simple and effective way to overcome this problem even for solutions with viscosities above 50 cP.

ACKNOWLEDGMENTS

The authors thank Coriolis Pharma (Martinsried, Germany) for the organizational and financial support, Sarah Zöls for her help regarding project initiation and Partikelmess- und Analysesysteme GmbH (Rutesheim, Germany) for providing the PAMAS SBSS light obscuration system and supporting the analytical work.

REFERENCES

1. Ph.Eur. 2.9.19. General, particulate contamination: sub-visible particles. Eur. Pharmacopoeia. 7th ed. 2011.
2. USP <788>. Particulate matter in injections. United States Pharmacopoeia, Natl. Formul. 2006.
3. Kirshner LS. Regulatory expectations for analysis of aggregates and particles. Talk at: Colorado Protein Stability Conference, Breckenridge, CO; 2012.
4. Jezek J, Rides M, Derham B, Moore J, Cerasoli E, Simler R, *et al.* Viscosity of concentrated therapeutic protein compositions. *Adv Drug Deliv Rev.* 2011;63(13):1107–17. Elsevier B.V.
5. Demeule B, Messick S, Shire SJ, Liu J. Characterization of particles in protein solutions: reaching the limits of current technologies. *AAPS J.* 2010;12(4):708–15.
6. USP <787>. Subvisible particulate matter in therapeutic protein injections—draft status. United States Pharmacopoeia, Natl. Formul.
7. Zöls S, Gregoritz M, Tantipolphan R, Wiggernhorn M, Winter G, Friess W, *et al.* How subvisible particles become invisible—relevance of the refractive index for protein particle analysis. *J Pharm Sci.* 2013;5:1–13.
8. Kamerzell TJ, Pace AL, Li M, Danilenko DM, McDowell M, Gokarn YR, *et al.* Polar solvents decrease the viscosity of high concentration IgG1 solutions through hydrophobic solvation and interaction: formulation and biocompatibility considerations. *J Pharm Sci.* 2013;102(4):1182–93.
9. Cao S, Narhi LO, Jiang Y. Analytical methods to measure sub-visible particulates. In: Mahler HC, Jiskoot W, editors. *Analysis of aggregates and particles in protein pharmaceuticals.* New York: Wiley; 2012.